FPRX Five Prime Therapeutics Inc.

35.33
-1.40  -4%
Previous Close 36.73
Open 36.92
Price To book 3.16
Market Cap 1021111264
Shares 28,902,102
Volume 307,405
Short Ratio 8.57
Av. Daily Volume 266,160

SEC filingsSee all SEC filings

  1. CT ORDER - Confidential treatment order 171073786
  2. 8-K - Current report 171054711
  3. 8-K - Current report 171052050
  4. 8-K/A [Amend] - Current report 171049450
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 171014987

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 initial data released at ASCO June 4, 2017.
Cabiralizumab (FPA008)
Pigmented Villonodular Synovitis (PVNS)
Phase 1b NSCLC halted, mesothelioma to continue. Data at ESMO showed ORR 48%.
FP-1039
Mesothelioma cancer

SEC Filings

  1. CT ORDER - Confidential treatment order 171073786
  2. 8-K - Current report 171054711
  3. 8-K - Current report 171052050
  4. 8-K/A [Amend] - Current report 171049450
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 171014987
  6. 8-K - Current report 171014840
  7. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 17956576
  8. 8-K - Current report 17923013
  9. CT ORDER - Confidential treatment order 17895263
  10. 8-K - Current report 17853426